A Phase 1/2 Study Of Bosutinib (SKI-606) In Philadelphia Chromosome Positive Leukemias

Trial Profile

A Phase 1/2 Study Of Bosutinib (SKI-606) In Philadelphia Chromosome Positive Leukemias

Phase of Trial: Phase I/II

Latest Information Update: 17 Jun 2018

At a glance

  • Drugs Bosutinib (Primary)
  • Indications Chronic myeloid leukaemia; Precursor cell lymphoblastic leukaemia-lymphoma
  • Focus Adverse reactions; Pharmacokinetics; Registrational; Therapeutic Use
  • Sponsors Pfizer; Wyeth Pharmaceuticals
  • Most Recent Events

    • 17 Jun 2018 Results assessing cross-intolerance (adverse events leading to discontinuation of both prior TKI and bosutinib) presented at the 23rd Congress of the European Haematology Association
    • 05 Jun 2018 Results of retrospective analysis assessing effects of bosutinib on renal function by using data from two studies including this study published in the Clinical Lymphoma, Myeloma & Leukemia.
    • 12 Dec 2017 Long-term results of cardiac, vascular and hypertensive safety of bosutinib from parent and extension studies presented at the 59th Annual Meeting and Exposition of the American Society of Hematology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top